• Latrunculin A: Stress-Testing Actin Mechanobiology

  2026-08-15

  Latrunculin A is more than an actin-disrupting reagent: it is a reversible mechanistic probe for testing how extracellular stiffness, Piezo1 signaling, and cytoskeletal remodeling shape cellular behavior. This article outlines a translational strategy for using Latrunculin A to distinguish upstream mechanosensing from downstream actin-dependent structure and function.

• Potassium Iodide in Research Workflows

  2026-08-14

  Potassium Iodide, or KI, is a practical iodide source for controlled thyroid-protection studies, uptake assays, and formulation compatibility experiments. This guide also shows where KI fits—and does not fit—in MMP-2-responsive liposome research involving sequential PD-1 pathway blockade and IDO inhibition.

• Ciprofloxacin: Mechanism and CREC Research

  2026-08-14

  Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. In a 2025 Guangdong study, carbapenemase-positive Enterobacter cloacae isolates showed significantly higher ciprofloxacin resistance than carbapenemase-negative isolates, supporting its use as a controlled research comparator rather than a universal treatment proxy.

• α2-adrenergic receptor agonist: Assay Strategy

  2026-08-13

  Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine can support α2-adrenergic receptor signaling research through a layered strategy that separates direct tumor effects from immune-mediated activity. The article translates recent osteosarcoma findings into practical model-selection, handling, and assay-design decisions.

• Nadolol (SQ-11725): Assay Reliability Guide

  2026-08-13

  This scenario-based guide explains how Nadolol (SQ-11725), SKU BA5097, can be incorporated into cell viability, proliferation, and cytotoxicity workflows without confusing beta-adrenergic effects with transporter-dependent exposure or assay artifacts. It combines product-handling facts with practical controls and cautiously interpreted pharmacokinetic evidence.

• A 83-01 in Breast AME Organoid Translation

  2026-08-12

  Patient-derived organoids can preserve the biology of rare breast tumors, but authenticity alone does not establish mechanism. This thought-leadership guide examines how A 83-01, a selective ALK-5 inhibitor, could be used as a disciplined TGF-β/Smad perturbation tool in adenomyoepithelioma organoid research while separating validated evidence from translational hypotheses.

• EZ Cap™ Cas9 mRNA for Neurodegeneration Studies

  2026-08-12

  EZ Cap™ Cas9 mRNA (5-moUTP) is an approximately 4548-nucleotide, Cap1-capped, polyadenylated Cas9 mRNA for guide RNA-dependent gene editing. It provides a practical research input for CRISPR-Cas9 genome editing in functional gene studies, while the cited zebrafish study defines biological targets and does not establish product-specific efficacy.

• Prochlorperazine in Melanoma: Evidence from COLO829 and C32

  2026-08-11

  The 2019 reference study examined prochlorperazine alongside perphenazine in melanotic COLO829 and amelanotic C32 melanoma cells, linking reduced viability and motility with changes in MITF and tyrosinase. Its main contribution is a phenotype-to-molecular analysis that positions a clinically familiar phenothiazine as a candidate for hypothesis-driven melanoma research, while also highlighting the limitations of extrapolating in vitro findings to treatment.

• ACSF3 Variant Links Human Height and Metabolic Rate

  2026-08-10

  The Cell Genomics study identifies rs34590044-A as an ancient regulatory variant associated with both greater human height and basal metabolic rate through increased ACSF3 expression, amino acid metabolic remodeling, and mitochondrial activity. Its combination of human genetics, functional regulatory analysis, mouse experiments, and ancient-DNA evidence provides a useful model for studying how dietary adaptation can shape coordinated physiological traits.

• PEGylated PLGA Microspheres for Extended Release

  2026-08-09

  Myers and Comolli developed and modeled PEGylated PLGA microspheres loaded with hydrocortisone 17-butyrate as a proof-of-concept platform for longer-acting intra-articular corticosteroid delivery. The study links emulsion optimization, avidin/biotin surface functionalization, and biphasic release modeling to reduced burst release and predominantly diffusion-controlled delivery over three weeks.

• TG003: A Mechanistic Guide to Clk Inhibition

  2026-08-08

  TG003 is a Cdc2-like kinase inhibitor that connects kinase selectivity with measurable changes in RNA processing. This guide explains how to interpret its biochemical, splicing, cancer, and exon-skipping applications without confusing target engagement with disease-specific efficacy.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-08-07

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, or otherwise difficult DNA templates where standard Taq-based PCR may be unreliable. It produces blunt-ended products for cloning, sequencing, and related workflows, but is not the appropriate choice when 3′-A overhangs or sticky ends are required.

• D-N-Acetylgalactosamine: Protocol Parameters for Brain Glyco

  2026-08-07

  D-N-Acetylgalactosamine is a high-purity, water-soluble metabolite tailored for analyzing glycoprotein constituents and glycosylation pathways in neurological research, particularly within brain heteropolysaccharide studies. It is not suitable for protocols requiring ethanol solubility or long-term storage of prepared solutions, and demands precise workflow control to ensure data integrity.

• H-89 and the Future of Bone Anabolism: Precision in cAMP-PKA

  2026-08-06

  This article explores how H-89, a selective cAMP-dependent protein kinase inhibitor, is transforming translational research in bone biology. Integrating recent mechanistic insights into Wnt-induced O-GlcNAcylation and metabolic rewiring, we provide actionable guidance for leveraging H-89 in cutting-edge workflows, highlight its strategic value over traditional tools, and envision its role in next-generation bone anabolic research.

• Leveraging (S)-(+)-Methoprene to Decode Juvenile Hormone Net

  2026-08-06

  (S)-(+)-Methoprene, a potent juvenile hormone analog, has emerged as a transformative tool for dissecting the molecular underpinnings of insect development and reproduction. This article explores how mechanistic insights—especially the interplay between miRNA–mRNA modules and Methoprene-tolerant receptor activation—are shaping experimental strategies for translational researchers. We present practical guidance for leveraging (S)-(+)-Methoprene in cutting-edge protocols, critically compare its unique attributes, and chart a visionary path for next-generation endocrine disruption studies.

453 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page